-
Uncategorized6 days agoOpinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
By the time the world began responding to the West Africa epidemic in 2014, which killed more than 11,000 people before it ended in 2016, there...
-
Uncategorized6 days ago
ADA: Obesity partners Zealand and Roche aim for weight loss ‘sweet spot’ with amylin agonist
Analysts and investors were unimpressed by Phase 2 data posted in the spring showing that an amylin analog developed by Roche and partner Zealand Pharma elicited...
-
Uncategorized6 days agoCDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures
NEW YORK — The Ebola outbreak in Central Africa could grow to 20,000 cases or more, depending on how quickly infected people are isolated to slow the spread,...
-
Uncategorized6 days agoSTAT+: Newer GLP-1s, pushback on research cuts, and a protest
You’re reading the web edition of STAT’s ADA in 30 Seconds newsletter from the American Diabetes Association’s annual conference. Sign up here This is Elizabeth Cooney...
-
Uncategorized6 days agoSTAT+: What stripping civil service protections for thousands of federal workers will mean for HHS
Thousands of Health and Human Services Department staff who shape policy, including on public health, federal health insurance programs, and health data privacy, have had their...
-
Uncategorized6 days ago
ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche...
-
Uncategorized6 days ago
How Germinal Centers Generate Antibodies Through Noisy Rounds of Mutation and Selection
A study tracking thousands of B cells across more than 100 germinal centers (GCs) in mice has revealed how the system consistently produces highly effective antibodies....
-
Uncategorized6 days ago
Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization
This week, Bio-Techne, a provider of life science tools, reagents, and diagnostic product, and Refeyn, a pioneer in mass photometry technology, announced the launch of an...
-
Uncategorized6 days agoStudy data convince Lundbeck to push new migraine drug forward
A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.
-
Uncategorized6 days agoA Billion-Dollar Deal, Trial Trouble, Biohub Updates, and Vaccine Research News
In this week’s episode, we start with news that Fulcrum Therapeutics is scrapping its lead pipeline program for sickle cell disease following concerns from the FDA...
An obesity drug deep-dive, and peptides move mainstream
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
